MFS
ADVM

Mirabella Financial Services’s Adverum Biotechnologies ADVM Stock Holding History

Mirabella Financial Services’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,420
Closed -$32K – 452
2022
Q1 		$32K Buy
+2,420
New +$35.4K ﹤0.01% 508

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Mirabella Financial Services's ADVM Position: Q2 2022 in Review

Mirabella Financial Services sold out of Adverum Biotechnologies (ADVM) in Q2 2022, closing a stake of 2,420 shares — an estimated $32K sold.

Mirabella Financial Services first reported a position in ADVM in Q1 2022 and held it in 1 quarter. The position peaked at $32K in Q1 2022. 77 funds tracked by Wall St. Rank hold ADVM as of Q2 2022.

  • Mirabella Financial Services reported no remaining Adverum Biotechnologies position as of Q2 2022 after selling out during the quarter.
  • Mirabella Financial Services sold 2,420 Adverum Biotechnologies shares in Q2 2022, an estimated $32K.
  • Mirabella Financial Services first reported a position in Adverum Biotechnologies in Q1 2022 and held it in 1 quarter.
  • Mirabella Financial Services's Adverum Biotechnologies position peaked at $32K in Q1 2022.
  • 77 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2022.

Based on Mirabella Financial Services's 13F filing for Q2 2022, filed 12 Aug 2022.